Refractory ventricular fibrillation treated with esmolol

详细信息    查看全文

• 作者：Young Hwan Lee^a ; ^b ; ^{hwaniyo@naver.com" class="auth_mail" title="E-mail the corresponding author} ; Kui Ja Lee^c ; ^{dlrnlwk@hanmail.net" class="auth_mail" title="E-mail the corresponding author} ; Yong Hun Min^a ; ^{xgaryx@naver.com" class="auth_mail" title="E-mail the corresponding author} ; Hee Cheol Ahn^a ; ^{gsemdr68@hallym.or.kr" class="auth_mail" title="E-mail the corresponding author} ; You Dong Sohn^a ; ^{medysohn@hallym.or.kr" class="auth_mail" title="E-mail the corresponding author} ; Won Woong Lee^a ; ^{woong421@naver.com" class="auth_mail" title="E-mail the corresponding author} ; Young Taeck Oh^a ; ^b ; ^{powerfreeze@hanmail.net" class="auth_mail" title="E-mail the corresponding author} ; Gyu Chong Cho^d ; ^{emdrcho@empal.com" class="auth_mail" title="E-mail the corresponding author} ; Jeong Yeol Seo^e ; ^{siris94@hallym.or.kr" class="auth_mail" title="E-mail the corresponding author} ; Dong Hyuk Shin^f ; ^{sinndhk@medimail.co.kr" class="auth_mail" title="E-mail the corresponding author} ; Sang O. Park^g ; ^{20080563@kuh.ac.kr" class="auth_mail" title="E-mail the corresponding author} ; Seung Min Park^a ; ^{aukawa1@naver.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Cardiopulmonary resuscitation ; Ventricular fibrillation ; Adrenergic beta-1 receptor antagonists
• 刊名：Resuscitation
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：107
• 期：Complete
• 页码：150-155
• 全文大小：798 K

文摘

This study aimed to evaluate the effects of esmolol treatment for patients with refractory ventricular fibrillation (RVF) in out-of-hospital cardiac arrest (OHCA).

Methods

This single-centre retrospective pre-post study evaluated patients who were treated between January 2012 and December 2015. Some patients had received esmolol (loading dose: 500 μg/kg, infusion: 0–100 μg/kg/min) for RVF (≥3 defibrillation attempts), after obtaining consent from the patient's guardian.

Results

Twenty-five patients did not receive esmolol (the control group), and 16 patients received esmolol. Sustained return of spontaneous circulation (ROSC) was significantly more common in the esmolol group, compared to the control group (56% vs. 16%, p = 0.007). Survival and good neurological outcomes at 30 days, 3 months and at 6 months were >2-fold better in the esmolol group, compared to the control group, although these increases were not statistically significant.

Conclusions

The findings of our study suggest that administration of esmolol may increase the rate of sustained ROSC and ICU survival among patients with RVF in OHCA. Further larger-scale, prospective studies are necessary to determine the effect of esmolol for RVF in OHCA.